Clinical Characteristics of Malignant Pericardial Effusion Associated with Recurrence and Survival
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose We evaluated clinical outcomes after drainage for malignant pericardial effusion with imminent or overt tamponade. Materials and Methods Between August 2001 and June 2007, 100 patients underwent pericardiocentesis for malignant pericardial effusion. Adequate follow-up information on the recurrence of pericardial effusion and survival status was available for 98 patients. Results Recurrence of effusion occurred in 30 patients (31%), all of whom were diagnosed with adenocarcinoma. Multivariate analysis indicated that adenocarcinoma of the lung (hazard ratio [HR], 6.6; 95% confidence interval [CI], 1.9 to 22.3; p=0.003) and progressive disease despite chemotherapy (HR, 4.3; 95% CI, 1.6 to 12.0; p=0.005) were independent predictors of recurrence. Survival rates three months after pericardiocentesis differed significantly with the type of primary cancer; the rates were 73%, 18%, 90% and 30% in patients with adenocarcinoma of the lung, squamous cell carcinoma of the lung, breast cancer and other cancers, respectively. Conclusion Recurrence and survival of patients with malignant pericardial effusion are dependent on the type of primary cancer and response to chemotherapy. Patients with adenocarcinoma of the lung may be good candidates for surgical drainage to avoid repeated pericardiocentesis, but pericardiocentesis is considered effective as palliative management in patients with other cancers.
Abstract
Purpose We evaluated clinical outcomes after drainage for malignant pericardial effusion with imminent or overt tamponade. Materials and Methods Between August 2001 and June 2007, 100 patients underwent pericardiocentesis for malignant pericardial effusion. Adequate follow-up information on the recurrence of pericardial effusion and survival status was available for 98 patients. Results Recurrence of effusion occurred in 30 patients (31%), all of whom were diagnosed with adenocarcinoma. Multivariate analysis indicated that adenocarcinoma of the lung (hazard ratio [HR], 6.6; 95% confidence interval [CI], 1.9 to 22.3; p=0.003) and progressive disease despite chemotherapy (HR, 4.3; 95% CI, 1.6 to 12.0; p=0.005) were independent predictors of recurrence. Survival rates three months after pericardiocentesis differed significantly with the type of primary cancer; the rates were 73%, 18%, 90% and 30% in patients with adenocarcinoma of the lung, squamous cell carcinoma of the lung, breast cancer and other cancers, respectively. Conclusion Recurrence and survival of patients with malignant pericardial effusion are dependent on the type of primary cancer and response to chemotherapy. Patients with adenocarcinoma of the lung may be good candidates for surgical drainage to avoid repeated pericardiocentesis, but pericardiocentesis is considered effective as palliative management in patients with other cancers.
참고문헌 (14)
- Klatt EC, "Cardiac metastases", Cancer, 65, pp.1456~1459 (1990)
- Laham RJ, "Pericardial effusion in patients with cancer: outcome with contemporary management strategies", Heart, 75, pp.67~71 (1996)
- Tsang TS, "Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy", Mayo Clin Proc, 75, pp.248~253 (2000)
- McDonald JM, "Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion", Ann Thorac Surg, 76, pp.811~815 (2003)
- Cullinane CA, "Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy", Chest, 125, pp.1328~1334 (2004)
- Maisch B, "Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin", Eur Heart J, 23, pp.1625~1631 (2002)
- Dequanter D, "Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival", Ann Surg Oncol, 15, pp.3268~3271 (2008)
- Gornik HL, "Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion", J Clin Oncol, 23, pp.5211~5216 (2005)
- García-Riego A, "Malignant pericardial effusion", Acta Cytol, 45, pp.561~566 (2001)
- Tsang TS, "Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years", Mayo Clin Proc, 77, pp.429~436 (2002)
- Feigenbaum H, "Echocardiography. 6th ed" (2005), Lippincott Williams & Wilkins
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Kim SH, "Initial echocardiographic characteristics of pericardial effusion determine the pericardial complications", International Journal of Cardiology, 136, pp.151~155 (2009)
- Allen KB, "Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage", Ann Thorac Surg, 67, pp.437~440 (1999)